Plan Group Financial LLC Purchases Shares of 935 Humana Inc. (NYSE:HUM)

Plan Group Financial LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 935 shares of the insurance provider’s stock, valued at approximately $296,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. grew its position in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the last quarter. Atwood & Palmer Inc. bought a new stake in Humana in the third quarter valued at $29,000. Hantz Financial Services Inc. bought a new stake in Humana in the second quarter valued at $35,000. Family Firm Inc. purchased a new position in Humana during the second quarter valued at $37,000. Finally, Hollencrest Capital Management purchased a new position in Humana during the second quarter valued at $40,000. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on HUM. Truist Financial lowered their price objective on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a research report on Friday, October 11th. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and lowered their price objective for the company from $519.00 to $253.00 in a research report on Monday, October 7th. Royal Bank of Canada lowered their price target on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Barclays lowered their price target on Humana from $364.00 to $250.00 and set an “equal weight” rating for the company in a research report on Thursday, October 10th. Finally, Bank of America lowered Humana from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $376.00 to $247.00 in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $315.33.

Humana Stock Down 0.0 %

NYSE HUM opened at $262.25 on Wednesday. The stock’s 50 day moving average is $312.24 and its 200 day moving average is $337.81. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $527.18. The stock has a market cap of $31.60 billion, a PE ratio of 16.33, a P/E/G ratio of 1.91 and a beta of 0.50.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $8.94 EPS. Research analysts predict that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.35%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.